Correction to: British Journal of Cancer (2014) 110, 2655–2661. doi:https://doi.org/10.1038/bjc.2014.209; published online 1 May 2014
Following the publication of this manuscript, it was recognised that an author name had been provided incorrectly. The correct name is A Ben Aissa. This name is now given in the author list above.
This work is published under the BJC's standard license to publish agreement. After 12 months the license terms will change to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.
Change history
20 March 2018
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at https://doi.org/10.1038/bjc.2014.209
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
About this article
Cite this article
Hottinger, A., Ben Aissa, A., Espeli, V. et al. Erratum: Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 118, e10 (2018). https://doi.org/10.1038/bjc.2017.469
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/bjc.2017.469
